Tyra Biosciences (TYRA) Conference August 21, 2025 11:00 AM ET Speaker0Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at HC Wainwright. It's my pleasure to welcome you to our HC Wainwright at home series. Today, we have Tyro Biosciences and from the company.I'm pleased to welcome CEO, Todd Harris, and CMO, Doug Warner. Thank you both for joining us today.Speaker1Thanks, Mitchell. It's great to be here.Speaker2Thanks for having us.Speaker0Great. Yeah. It's our pleasure. So, yeah, w ...

Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology [2] - The company utilizes its in-house precision medicine platform, SNÅP, for rapid and precise drug design, predicting genetic alterations that may cause resistance to existing therapies [2] - Tyra's lead product, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor designed to minimize toxicities associated with other FGFR inhibitors [2] Group 2 - Current clinical development plans for dabogratinib include studies for intermediate risk non-muscle invasive bladder cancer, pediatric achondroplasia, and potential future studies for metastatic urothelial cancer [2] - Tyra is also developing TYRA-430, an oral FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, and TYRA-200, an oral FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma [2] - The company will participate in investor events, including a virtual fireside chat on August 21, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025 [1]